Terrorist Attacks Have No Impact on EuroMeeting, Says DIA
Applied Clinical Trials
Efforts are escalating to encourage sponsors, research institutions, and clinical investigators to accept oversight for multi-center studies by central institutional review boards (IRBs), as seen in several discussions of this topic at the December conference on "Advancing Ethical Research" sponsored by Public Responsibility in Medicine & Research.
The combined EuroMeeting and Clinical Forum, slated for mid-April, will take place in Paris as planned, in spite of January's terrorist attacks in the French capital, according to the Drug Information Association (DIA).
"We are working closely with the venue and the city of Paris to make sure all security measures are taken and on-site security will be reinforced," says Natacha Scholl, team leader of operations for DIA in Europe, Middle East & Africa. "We will put everything in place to reassure participants, of course."
Scholl does not anticipate that the attacks will have any great impact on delegate numbers. "Registrations haven't stopped over the past days, despite the tragic events," she says.
As of Jan. 15, there were already more than 650 registered participants, and Scholl said the organizers are expecting at least 2,500 to 3,000 attendees in total for the two events. The EuroMeeting and Clinical Forum have never before been held at the same location, but there were around 2,500 participants at the 2013 EuroMeeting in Amsterdam and around 2,200 at the 2014 EuroMeeting in Vienna. The Clinical Forum attracts an average of 400 attendees each year.
Globalization remains a key industry trend and one that will be discussed heavily at both events. The continued significance of global markets was listed as the 10th leading trend in pharmaceuticals, according to DIA's second annual "What Lies Ahead?" report.
"It is important for companies to work in global markets, especially in developing markets like China, pan-Asia, Russia and Eastern Europe, India, and Brazil, Argentina, Venezuela, and other Latin American countries, as this is where the majority of future growth will be," wrote the authors.
Successful companies, they said, conduct early stage analysis and planning to account for varying global factors when selecting countries for expansion, and they also create partnerships to address these needs and to build infrastructure, including training of the workforce.
According to the DIA report, "The topic of global markets is, as one thought leader expressed, 'almost an established fact of life and no longer a trend.'"
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
